Association of Pro-inflammatory Cytokines with Gastric Cancer Risk: A Case-Cohort Study.

IF 4.1 2区医学 Q2 ONCOLOGY

Cancer Research and Treatment Pub Date : 2024-11-19 DOI:10.4143/crt.2024.718

Seungju Baek, Eunjung Park, Eun Young Park

{"title":"Association of Pro-inflammatory Cytokines with Gastric Cancer Risk: A Case-Cohort Study.","authors":"Seungju Baek, Eunjung Park, Eun Young Park","doi":"10.4143/crt.2024.718","DOIUrl":null,"url":null,"abstract":"Purpose: This study aimed to assess the association between inflammatory cytokines and the risk of gastric cancer (GC).Materials and methods: We conducted a case-cohort study using Korean National Cancer Center Community (KNCCC) cohort data to investigate the associations between pro-inflammatory, anti-inflammatory cytokines, inflammatory mediators, and GC risk in the Korean general population (GC cases: n=159, subcohort: n=822). Serum levels of inflammatory cytokines were measured using Quantikine® ELISA and analyzed using a Cox proportional hazards regression model.Results: Compared to those with the lowest serum interleukin 6 (IL-6) levels, the risk of GC significantly increased in the second (HR: 3.48 [1.73-6.99]), third (HR: 3.74 [1.91-7.29], and fourth quartiles (HR: 3.79 [1.93-7.48]). Elevated levels of interleukin 1β (IL-1β) (HR: 1.57 [1.12-2.21]) and interferon gamma (IFN-γ) (HR: 2.49 [1.73-3.58]) were also associated with an increased risk of GC.Conclusion: The findings of this study indicate associations between pro-inflammatory cytokines (IL-6, IL-1β, and IFN-γ) and the risk of GC, suggesting that regulating these cytokine levels may aid in GC prevention.","PeriodicalId":49094,"journal":{"name":"Cancer Research and Treatment","volume":" ","pages":""},"PeriodicalIF":4.1000,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Research and Treatment","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4143/crt.2024.718","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: This study aimed to assess the association between inflammatory cytokines and the risk of gastric cancer (GC).

Materials and methods: We conducted a case-cohort study using Korean National Cancer Center Community (KNCCC) cohort data to investigate the associations between pro-inflammatory, anti-inflammatory cytokines, inflammatory mediators, and GC risk in the Korean general population (GC cases: n=159, subcohort: n=822). Serum levels of inflammatory cytokines were measured using Quantikine® ELISA and analyzed using a Cox proportional hazards regression model.

Results: Compared to those with the lowest serum interleukin 6 (IL-6) levels, the risk of GC significantly increased in the second (HR: 3.48 [1.73-6.99]), third (HR: 3.74 [1.91-7.29], and fourth quartiles (HR: 3.79 [1.93-7.48]). Elevated levels of interleukin 1β (IL-1β) (HR: 1.57 [1.12-2.21]) and interferon gamma (IFN-γ) (HR: 2.49 [1.73-3.58]) were also associated with an increased risk of GC.

Conclusion: The findings of this study indicate associations between pro-inflammatory cytokines (IL-6, IL-1β, and IFN-γ) and the risk of GC, suggesting that regulating these cytokine levels may aid in GC prevention.

查看原文本刊更多论文

前炎症细胞因子与胃癌风险的关系：一项病例队列研究。

目的：本研究旨在评估炎性细胞因子与胃癌（GC）发病风险之间的关系：我们利用韩国国立癌症中心社区（KNCCC）队列数据开展了一项病例队列研究，以调查韩国普通人群（胃癌病例：n=159，亚队列：n=822）中促炎、抗炎细胞因子、炎症介质与胃癌风险之间的关联。使用Quantikine® ELISA测定血清中的炎症细胞因子水平，并使用Cox比例危险回归模型进行分析：结果：与血清白细胞介素 6 (IL-6) 水平最低的人群相比，血清白细胞介素 6 (IL-6) 水平在第二四分位数（HR：3.48 [1.73-6.99]）、第三四分位数（HR：3.74 [1.91-7.29]）和第四四分位数（HR：3.79 [1.93-7.48]）的人群患 GC 的风险显著增加。白细胞介素 1β （IL-1β）（HR：1.57 [1.12-2.21]）和γ干扰素（IFN-γ）（HR：2.49 [1.73-3.58]）水平升高也与 GC 风险增加有关：本研究结果表明，促炎细胞因子（IL-6、IL-1β 和 IFN-γ）与 GC 风险之间存在关联，这表明调节这些细胞因子水平可能有助于预防 GC。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Research and Treatment ONCOLOGY-

CiteScore

8.00

自引率

2.20%

发文量

126

审稿时长

>12 weeks

期刊介绍： Cancer Research and Treatment is a peer-reviewed open access publication of the Korean Cancer Association. It is published quarterly, one volume per year. Abbreviated title is Cancer Res Treat. It accepts manuscripts relevant to experimental and clinical cancer research. Subjects include carcinogenesis, tumor biology, molecular oncology, cancer genetics, tumor immunology, epidemiology, predictive markers and cancer prevention, pathology, cancer diagnosis, screening and therapies including chemotherapy, surgery, radiation therapy, immunotherapy, gene therapy, multimodality treatment and palliative care.